Your institution may have access to this item. Find your institution then sign in to continue.
Title
PARP inhibitor approved, despite vote.
Abstract
The article reports that the drug Lynparza from the pharmaceutical firm AstraZeneca for treating ovarian cancer linked to specific genetic mutations has been approved by the U.S. Food and Drug Administration despite an earlier negative panel vote against drug recommendation.